Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
14,273 people get ABT articles and Market Currents by email alert.
Get email alerts on ABT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30 -
-
-
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Abbott Hopes Mitral Repair Will Be The New TAVIEP Vantage • Wed, Feb 27 -
-
-
-
-
-
-
-
Abbott Earnings Preview: What We Are WatchingTrefis • Tue, Jan 22
-
-
Abbott Laboratories' Management Presents HCV Program Update (Transcript)Mon, Nov 12, 2012
-
Abbott Laboratories Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Abbott Laboratories Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
Abbott Laboratories, Q3 2009 Earnings Call TranscriptWed, Oct 14, 2009
-
Abbott Laboratories, Q2 2009 Earnings Call TranscriptWed, Jul 15, 2009 • 1 Comment
-
Abbott Laboratories Q1 2009 Earnings Call TranscriptFri, Apr 17, 2009
-
Abbott Laboratories Q4 2008 Earnings Call TranscriptWed, Jan 21, 2009
-
Abbott Laboratories Q3 2008 Earnings Call TranscriptWed, Oct 15, 2008
-
at CNBC.com (Fri, 6:29PM)
-
at CNBC.com (Fri, 6:02PM)
-
at CNBC.com (May 13, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
at CNBC.com (Mar 20, 2013)
-
at CNBC.com (Mar 11, 2013)
-
at CNBC.com (Feb 14, 2013)
-
at MarketWatch.com (Jan 30, 2013)
-
at MarketWatch.com (Jan 23, 2013)
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable revenue segments: Pharmaceutical Products, Diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, January 31, 4:09 PM Despite the marketshare gains Cardiovascular Systems (CSII) has made with its Diamondback and Stealth devices for treating narrowed or blocked arteries in the leg, the real value in the company may lie in its takeout potential, says Seeking Alpha contributor Stephen Simpson. CR Bard, Cook, BSX, JNJ, MDT and ABT all have sales forces in the peripheral treatment space, making them solid candidates for a possible buyout of CSII. Comment! [Healthcare, M&A]
- Tuesday, January 8, 7:26 PM Nestle (NSRGY.PK) is looking to sell nearly $1B of its Latin American assets in an effort to secure regulatory approval for its $12B purchase of Pfizer's (PFE) nutrition unit. The company is in the early stages of the process, with the assets potentially drawing interest from H.J. Heinz (HNZ), Danone (DANOY.PK), Abbott Laboratories (ABT) and Mead Johnson Nutrition (MJN). Comment! [Consumer, Global & FX, M&A]
- Thursday, January 3, 5:08 PM Abbott Labs (ABT), Johnson & Johnson (JNJ) and Sanofi (SNY) have all displayed an interest in Warburg Pincus' Bausch & Lomb. Warburg, working through Goldman Sachs (GS), is hoping to get at least $10B for the business and is seeking first-round bids by month’s end. The $10B price tag would be a major coup for Warburg, raking in a 200% return off its $1.7b equity investment. 1 Comment [Healthcare, M&A]
- Tuesday, December 11, 2012, 6:48 PM Goldman Sachs (GS) gets the nod by Warburg Pincus to explore a sale of Bausch & Lomb, the company's eye-care division. Warburg is said to be seeking at least $10B for the business. According to reports, Goldman has already contacted Sanofi (SNY), GlaxoSmithKline (GSK), and Merck (MRK) this month, and that Abbott Laboratories (ABT) will be among the other companies contacted. Comment! [Healthcare, M&A]
- Wednesday, February 29, 2012, 7:45 AM Galapagos CEO Onno van de Stolpe calls the development deal with Abbott Laboratories (ABT) announced earlier today the "largest Phase 2 deal in the history of the industry." The agreement will line up Abbott in competition with Pfizer (PFE) in a race to develop a widely used rheumatoid arthritis drug. Shares of Galapagos are up 22% in Brussels trading. 2 Comments [M&A, Global & FX, Healthcare]
- Tuesday, January 31, 2012, 11:21 AM Companies lining up to take a hard look at buying a stake in Turkish drugmaker Mustafa Nevzat Ilac Sanayii in a deal that may value the company at $1B include GSK, LLY, PFE, ABT and MYL. Merrill Lynch reportedly has sent teasers to potential bidders and non-binding bids have begun to arrive; bidding may be done within two months. Comment! [Healthcare, M&A]
- Thursday, January 12, 2012, 5:03 PM Nestle (NSRGY.PK) and Danone (DANOY.PK) have made initial bids for Pfizer's (PFE) baby-formula division, reports Bloomberg. However, sources claim Pfizer may still opt to spin off the business rather than sell it. It was claimed in July that the unit could fetch as much as $10.5B. Yesterday, Abbott Laboratories (ABT) said it isn't interested in making a bid. Comment! [Consumer, M&A]
- Friday, July 29, 2011, 3:03 AM Nestle (NSRGY.PK) , Danone (DANOY.PK) and Abbott Laboratories (ABT) are likely to bid for Pfizer's (PFE) infant-nutrition unit, sources say. Pfizer intends to send information to prospective suitors in September about the subsidiary, which may fetch up to $10.5B. (previous) Comment! [M&A]
-
- View all 0 replies
-
- View all 0 replies
-
Derek A. Barrett
Sold $ABBV after reaching 50% Graham profit target. Still holding $ABT in 401k. I am seriously running out of value ideas ! - View all 15 replies
-
Derek A. Barrett: Thanks for the info guys! Bret Jensen also did an article on the Street when $CBI was about 10% lower, so looks like a solid pickup.
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 4 replies
-
Minutemen: INTC up over $22 on a broad market sell off. Gotta like that. Investors starting to see INTC's value.
-
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Derek A. Barrett
Sold $ABBV after reaching 50% Graham profit target. Still holding $ABT in 401k. I am seriously running out of value ideas ! - View all 15 replies
-
Derek A. Barrett: Thanks for the info guys! Bret Jensen also did an article on the Street when $CBI was about 10% lower, so looks like a solid pickup.
-
-
- View all 13 replies
-
-
Derek A. Barrett: Not sure if anyone is still following this thread, but $ABBV has hit my 50% Graham profit target so I will be selling. Great job $ABBV!
-
- View all 1 replies
-
-
- View all 4 replies
-
Minutemen: INTC up over $22 on a broad market sell off. Gotta like that. Investors starting to see INTC's value.
-
-
- View all 1 replies
-
Minutemen: Yeah, RSI is in oversold territory. I'm long ABT so will just ride it out.
-
- View all 3 replies
-
SKS1586: Thanks my friend. I am a Trader. I increase & reduce position frequently. I sell with small profit to create CASH for other opportunities.
-
SKS1586: Rubenov: You are correct. Correction may happen anytime. I work predominantly with Turnarounds + Scale in slowly & remove profit every week.
-
- View all 2 replies
-
-
SKS1586: joe kelly - I reduce or remove my positions for creation of CASH. Therefore I leave trades with much less profit than most Investors/Traders
-
- View all 5 replies
-
Brennan Basnicki: Yah looks like it. I was really bullish, but a few key trend lines probably will be taken out. Will be seeing how $ANR and $WLT react
-
-
- View all 3 replies
-
Brennan Basnicki: No, haven't tried any shorts for a while. Any time I have they have been short term, with recent one's being losers unfortunately!
-
Brennan Basnicki: The chart is actually pretty bullish right now, however I am bearish on fundamentals. In any case, I don't expect to trade it anytime soon
-
- View all 7 replies
-
Minutemen: Yes. See the following article (in which the author proposes selling ABBV and buying more ABT): http://on-msn.com/ZBOUmr
-
-
Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them - View all 1 replies
-
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
-
- View all 3 replies
-
-
-
Brodidliy1
I've done pretty well with Abbot Labs (ABT). Think I should take some profits or keep my shares ahead of the company split? - View all 2 replies
-
-
Brodidliy1: Still reading through the quarterly report, but I think I like the long term prospects of the abt post split. Had a great run though
-
- View all 3 replies
-
-
-
- View all 3 replies
-
-
